Performance Analysis:

ADMA Biologics, Inc. is a commercial biopharmaceutical company that is dedicated to producing, marketing, and developing specialty plasma-derived biologics for the treatment of immune-compromised patients. The company currently has three products approved by the FDA, and all are commercially available. The products include BIVIGAM, ASCENIV, and Nabi-HB. During the period under review, the company experienced an increase in revenue, mainly due to the sale of products to treat immune-compromised individuals. The company also increased its plasma collection centers' operational capacity by expanding its supply chain network and increasing the FDA approved facilities to ten sites. 

During the period under review, the company's revenue increased, while its operational expenses decreased, leading to improved profitability. Additionally, the plasma-derived intermediate fractions sold to third parties increased revenue. The company's business model of providing laboratory contracting services also contributed to the company's financial growth. By providing services such as contract filling, labeling, and packing services, the company has established additional revenue streams to expand their customer base.

Future outlook:

ADMA Biologics, Inc. aims to continue producing immune globulin products with standardized antibodies that target different serotypes of S. pneumonia. The company seeks to expand its plasma collection centers by increasing the number of licensed FDA centers to ten by the end of 2023. By doing so, the company plans to increase revenue by producing sufficient quantities of its immune globulin products, resulting in approximately $210 million in revenue in 2023, and in excess of $300 million in annual revenue after 2024. It is expected that the company will achieve this revenue level by leveraging production yields and its ongoing supply chain and capacity expansion initiatives. Additionally, the gross and net income margins of the company are predicted to range between 40%-50% and 20%-30%, respectively, in 2024-2025.

Moreover, ADMA Biologics, Inc. seeks to enter into contract manufacturing services for third-party clients and laboratory contracting services. The company aims to achieve a competitive position in the biopharmaceutical industry through its strategy of focusing on the production of plasma-derived biologics for immune-compromised patients, and providing high-quality services to its customers at cost-effective rates. 

The company also aims to respond to changes in the market by keeping abreast of current trends in the industry through strategic partnerships and collaborations. The management team of the company is well experienced and has implemented various initiatives to drive the company's growth, which are well-aligned with the demands and needs of the market.  As per the company's management, "We believe that our products and product candidates will offer unique and valuable contributions to the medical community, particularly as resistance to antibiotics becomes more prevalent, and as certain geographic regions remain susceptible to various infectious diseases."

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Adma Biologics Inc

ADMA Biologics' revenue up, targeting $210M in 2023

Analyst Summary:

ADMA Biologics has announced its Q4 and full year financial results for 2022, and provided a business update. The company reported Q4 revenue of $50.2M, up from $14.3M in the same period in 2021, due to increased sales of its ASCENIV product. Additionally, the company reported its focus on the immune-deficient patient segment has led to a record number of patients treated, and strong market share gains. ADMA Biologics has identified opportunities to potentially grow peak revenues and earnings beyond prior guidance. The report also forecasts that first-time positive EBITDA is expected no later than the second half of 2023. The company remains highly committed to driving profitability in the periods ahead. Higher gross profit was driven by sales of ASCENIV and this favorable mix is expected to continue in the coming months. While ADMA sold a significant amount of lower margin product in the fourth quarter of 2022, it is anticipated that the lower margin inventory will be exhausted soon. Finally, the company plans to expand its portfolio of products in the near future.

Form 8-K - Current report - Item 2.02 Item 9.01

$ADMA reports record revenue growth, opportunities for future earnings, and expanded product portfolio.

Form 8-K - Current report - Item 5.02 Item 9.01

Announcement: ADMA 8-K Special Filing

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

ADMA Biologics' revenue up, targeting $210M in 2023

ADMA Biologics' revenue up, targeting $210M in 2023

$ADMA reports record revenue growth, opportunities for future earnings, and expanded product portfolio.

$ADMA reports record revenue growth, opportunities for future earnings, and expanded product portfolio.

Announcement: ADMA 8-K Special Filing

Announcement: ADMA 8-K Special Filing

Announcement: ADMA SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ADMA SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ADMA SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ADMA SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ADMA SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ADMA SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment